Nuvalent

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent's mission is to develop and provide innovative products and services that improve health outcomes and provide superior customer service.

At Nuvalent, we are committed to creating a healthier future by leveraging leading edge technologies and novel manufacturing techniques. Our goal is to improve health outcomes and make life-saving treatments more accessible to all.

Nuvalent has won numerous awards for its pioneering products and services. In 2019, the company was recognized as the Best Medical Device Manufacturer of the Year at the Global Biotech Awards. The company was also awarded the Corporate Social Responsibility Award by the World Economic Forum in 2020, in recognition of its commitment to developing innovative products with a positive social impact.